Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Cut by Simmons Bank

Simmons Bank decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 60.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,807 shares of the medical equipment provider's stock after selling 10,612 shares during the quarter. Simmons Bank's holdings in Zimmer Biomet were worth $828,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. PFG Advisors grew its holdings in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider's stock valued at $231,000 after purchasing an additional 84 shares during the period. Quent Capital LLC increased its holdings in Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider's stock worth $63,000 after acquiring an additional 92 shares in the last quarter. Financial Advocates Investment Management raised its position in Zimmer Biomet by 3.8% during the third quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider's stock worth $295,000 after acquiring an additional 97 shares during the period. Stokes Family Office LLC lifted its holdings in Zimmer Biomet by 4.1% during the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider's stock valued at $280,000 after purchasing an additional 99 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its position in shares of Zimmer Biomet by 15.6% in the third quarter. Parkside Financial Bank & Trust now owns 756 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 102 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.70% of the company's stock.

Analysts Set New Price Targets

ZBH has been the subject of several research reports. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, May 2nd. Truist Financial reduced their target price on shares of Zimmer Biomet from $137.00 to $130.00 and set a "hold" rating for the company in a research report on Friday, May 3rd. Royal Bank of Canada restated an "outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 9th. Oppenheimer upped their price objective on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an "outperform" rating in a research note on Friday, May 3rd. Finally, Citigroup raised their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $135.40.

Zimmer Biomet Trading Down 0.5 %

Shares of Zimmer Biomet stock traded down $0.58 on Wednesday, reaching $120.85. The company had a trading volume of 1,238,856 shares, compared to its average volume of 1,476,388. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. The firm has a market cap of $24.86 billion, a PE ratio of 26.16, a PEG ratio of 2.18 and a beta of 1.03. The firm's 50 day moving average price is $125.07 and its two-hundred day moving average price is $120.44. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the previous year, the company earned $1.89 earnings per share. The firm's quarterly revenue was up 3.2% compared to the same quarter last year. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.09 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were paid a dividend of $0.24 per share. The ex-dividend date was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet's dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.